Aripiprazole in the treatment of irritability in pediatric patients (Aged 6-17 Years) with autistic disorder: Results from a 52-week, open-label study

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 3, 2011, Pages 229-236

  Marcus, Ronald N ^a   Owen, Randall ^a   Manos, George ^a   Mankoski, Raymond ^a   Kamen, Lisa ^a   McQuade, Robert D ^b   Carson, William H ^b   Corey Lisle, Patricia K ^a   Aman, Michael G ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; BENZATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPHENHYDRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESZOPICLONE; MELATONIN; MOOD STABILIZER; PLACEBO; PROPRANOLOL; PSYCHOSTIMULANT AGENT; ZOLPIDEM;

ADOLESCENT; AGGRESSION; ARTICLE; AUTISM; BEHAVIOR DISORDER; BEHAVIOR MODIFICATION; CHILD; CHILD BEHAVIOR; CHILD BEHAVIOR CHECKLIST; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEVER; HUMAN; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRESCHOOL CHILD; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SPEECH DISORDER; STEREOTYPY; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRRITABLE MOOD; MALE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; TREATMENT OUTCOME;

EID: 79958786682     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2009.0121     Document Type: Article

References (17)

1. Aman MG, Singh NN, Stewart AW, Field CJ: The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491, 1985a. (Pubitemid 15104762)
2. Aman MG, Singh NN, Stewart AW, Field CJ: Psychometric characteristics of the Aberrant Behavior Checklist. Am J Ment Defic 89: 492-502, 1985b. (Pubitemid 15104763)
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
4. Aripiprazole: (Abilify) U.S. Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb and Rockville MD: Otsuka America Pharmaceutical, Inc.; 2009.
5. Brannan MA, Heflinger CA, Bickman L: The Caregiver Strain Questionnaire. Measuring the impact on the family of living with a child with serious emotional disturbance. J Emot Behav Disord 5: 212-222, 1997.
6. Correll CU: Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 69 Suppl 4:26-36, 2008.
7. Guy W: ECDEU Assessment Manual for Psychopharmacology- Revised. Rockville, MD: US Department of Health Services; 1976.
8. Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview- Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659-685, 1994. (Pubitemid 24309810)
9. Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Findling RL: A 52-week, open-label, multicenter study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of irritability in pediatric patients (6-17 years) with autistic disorder. J Clin Psychiatry In press.
10. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG: A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48: 1110-1119, 2009.
11. Myers SM, Johnson CP: Management of children with autism spectrum disorders. Pediatrics 120:1162-1182, 2007. (Pubitemid 350085560)
12. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL: Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533-1540, 2009.
13. Risperidone: (Risperdal) U.S. Full Prescribing Information. Titusville NJ: Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc.; 2009.
14. Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF: Childrens Yale-Brown Obsessive Compulsive Scale: Reliability and validity. J Am Acad Child Adolesc Psychiatry 36:844-852, 1997. (Pubitemid 27250450)
15. Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P: The PedsQLTM in pediatric cancer: Reliability and validity of the Pediatric Quality of Life InventoryTM Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer 94:2090-2106, 2002. (Pubitemid 34270065)
16. Varni JW, Seid M, Kurtin PS: PedsQLTM 4.0: reliability and validity of the Pediatric Quality of Life InventoryTM version 4.0 Generic Core Scales in healthy and patient populations. Med Care 39:800-812, 2001. (Pubitemid 33686263)
17. Volkmar F, Cook EH, Jr., Pomeroy J, Realmuto G, Tanguay P: Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 38:32S-54S, 1999.